Does the media prefer KYTX or ZYME?

In the previous week, Zymeworks had 2 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 5 mentions for Zymeworks and 3 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 1.61 beat Zymeworks' score of 1.50 indicating that Kyverna Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Zymeworks 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor STOK or KYTX?

In the previous week, Kyverna Therapeutics had 1 more articles in the media than Stoke Therapeutics. MarketBeat recorded 3 mentions for Kyverna Therapeutics and 2 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.75 beat Kyverna Therapeutics' score of 1.61 indicating that Stoke Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Kyverna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable valuation and earnings, NBTX or KYTX?

Nanobiotix has higher revenue and earnings than Kyverna Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanobiotix $36.87M 50.81 -$27.11M N/A N/A Kyverna Therapeutics N/A N/A -$161.31M -$2.94 N/A

Is NBTX or KYTX more profitable?

Nanobiotix's return on equity of 0.00% beat Kyverna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Nanobiotix N/A N/A N/A Kyverna Therapeutics N/A -81.92% -63.74%

Does the media refer more to NBTX or KYTX?

In the previous week, Nanobiotix and Nanobiotix both had 3 articles in the media. Kyverna Therapeutics' average media sentiment score of 1.61 beat Nanobiotix's score of 0.87 indicating that Kyverna Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kyverna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer KYTX or VIR?

In the previous week, Kyverna Therapeutics and Kyverna Therapeutics both had 3 articles in the media. Kyverna Therapeutics' average media sentiment score of 1.61 beat Vir Biotechnology's score of 1.29 indicating that Kyverna Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Vir Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KYTX or XNCR?

In the previous week, Kyverna Therapeutics and Kyverna Therapeutics both had 3 articles in the media. Xencor's average media sentiment score of 1.75 beat Kyverna Therapeutics' score of 1.61 indicating that Xencor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Xencor 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Kyverna Therapeutics (KYTX) Competitors

$7.26 -0.09 (-1.22%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$7.28 +0.02 (+0.22%)

As of 09/11/2026 07:30 PM Eastern

Compare

KYTX vs. ZYME, STOK, NBTX, VIR, and XNCR

Should you buy Kyverna Therapeutics stock or one of its competitors? Kyverna Therapeutics's main competitors and comparable companies include Zymeworks (ZYME), Stoke Therapeutics (STOK), Nanobiotix (NBTX), Vir Biotechnology (VIR), and Xencor (XNCR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kyverna Therapeutics compare to Zymeworks?

Kyverna Therapeutics (NASDAQ:KYTX) and Zymeworks (NASDAQ:ZYME) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Kyverna Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 313.22%. Zymeworks has a consensus target price of $41.00, indicating a potential upside of 56.25%. Given Kyverna Therapeutics' higher possible upside, equities analysts plainly believe Kyverna Therapeutics is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Zymeworks has higher revenue and earnings than Kyverna Therapeutics. Zymeworks is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$2.94	N/A
Zymeworks	$105.96M	17.57	-$81.13M	-$2.02	N/A

18.1% of Kyverna Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 17.6% of Kyverna Therapeutics shares are owned by company insiders. Comparatively, 33.5% of Zymeworks shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Kyverna Therapeutics has a net margin of 0.00% compared to Zymeworks' net margin of -405.31%. Zymeworks' return on equity of -72.30% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.92%	-63.74%
Zymeworks	-405.31%	-72.30%	-37.18%

Kyverna Therapeutics has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market. Comparatively, Zymeworks has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market.

In the previous week, Zymeworks had 2 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 5 mentions for Zymeworks and 3 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 1.61 beat Zymeworks' score of 1.50 indicating that Kyverna Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Zymeworks	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zymeworks beats Kyverna Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Stoke Therapeutics?

Stoke Therapeutics (NASDAQ:STOK) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Stoke Therapeutics has higher revenue and earnings than Kyverna Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$184.42M	10.16	-$6.89M	-$3.34	N/A
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$2.94	N/A

Kyverna Therapeutics has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -753.60%. Stoke Therapeutics' return on equity of -59.36% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-753.60%	-59.36%	-51.46%
Kyverna Therapeutics	N/A	-81.92%	-63.74%

Stoke Therapeutics presently has a consensus target price of $44.25, indicating a potential upside of 52.43%. Kyverna Therapeutics has a consensus target price of $30.00, indicating a potential upside of 313.22%. Given Kyverna Therapeutics' higher probable upside, analysts plainly believe Kyverna Therapeutics is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

18.1% of Kyverna Therapeutics shares are owned by institutional investors. 9.6% of Stoke Therapeutics shares are owned by company insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Kyverna Therapeutics had 1 more articles in the media than Stoke Therapeutics. MarketBeat recorded 3 mentions for Kyverna Therapeutics and 2 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.75 beat Kyverna Therapeutics' score of 1.61 indicating that Stoke Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Kyverna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Stoke Therapeutics has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 1.98, meaning that its share price is 98% more volatile than the broader market.

Summary

Stoke Therapeutics and Kyverna Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Nanobiotix?

Nanobiotix (NASDAQ:NBTX) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

Nanobiotix currently has a consensus price target of $37.33, indicating a potential upside of 0.87%. Kyverna Therapeutics has a consensus price target of $30.00, indicating a potential upside of 313.22%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kyverna Therapeutics is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Nanobiotix's return on equity of 0.00% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Kyverna Therapeutics	N/A	-81.92%	-63.74%

Nanobiotix has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 1.98, meaning that its stock price is 98% more volatile than the broader market.

In the previous week, Nanobiotix and Nanobiotix both had 3 articles in the media. Kyverna Therapeutics' average media sentiment score of 1.61 beat Nanobiotix's score of 0.87 indicating that Kyverna Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kyverna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

38.8% of Nanobiotix shares are owned by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by company insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Nanobiotix has higher revenue and earnings than Kyverna Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.87M	50.81	-$27.11M	N/A	N/A
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$2.94	N/A

Summary

Nanobiotix and Kyverna Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Vir Biotechnology?

Kyverna Therapeutics (NASDAQ:KYTX) and Vir Biotechnology (NASDAQ:VIR) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

Kyverna Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 313.22%. Vir Biotechnology has a consensus price target of $21.57, suggesting a potential upside of 103.12%. Given Kyverna Therapeutics' higher possible upside, analysts plainly believe Kyverna Therapeutics is more favorable than Vir Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Kyverna Therapeutics has a beta of 1.98, meaning that its share price is 98% more volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.63, meaning that its share price is 63% more volatile than the broader market.

Kyverna Therapeutics has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -29.99% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.92%	-63.74%
Vir Biotechnology	-638.88%	-29.99%	-23.62%

In the previous week, Kyverna Therapeutics and Kyverna Therapeutics both had 3 articles in the media. Kyverna Therapeutics' average media sentiment score of 1.61 beat Vir Biotechnology's score of 1.29 indicating that Kyverna Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Vir Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

18.1% of Kyverna Therapeutics shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 17.6% of Kyverna Therapeutics shares are owned by insiders. Comparatively, 2.9% of Vir Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Kyverna Therapeutics has higher earnings, but lower revenue than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$2.94	N/A
Vir Biotechnology	$68.56M	26.21	-$437.99M	-$1.86	N/A

Summary

Vir Biotechnology beats Kyverna Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Xencor?

Kyverna Therapeutics (NASDAQ:KYTX) and Xencor (NASDAQ:XNCR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Kyverna Therapeutics has a net margin of 0.00% compared to Xencor's net margin of -155.59%. Xencor's return on equity of -28.66% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.92%	-63.74%
Xencor	-155.59%	-28.66%	-20.38%

In the previous week, Kyverna Therapeutics and Kyverna Therapeutics both had 3 articles in the media. Xencor's average media sentiment score of 1.75 beat Kyverna Therapeutics' score of 1.61 indicating that Xencor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Xencor	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Kyverna Therapeutics currently has a consensus target price of $30.00, suggesting a potential upside of 313.22%. Xencor has a consensus target price of $31.86, suggesting a potential upside of 30.51%. Given Kyverna Therapeutics' higher probable upside, research analysts clearly believe Kyverna Therapeutics is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Xencor	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67

18.1% of Kyverna Therapeutics shares are held by institutional investors. 17.6% of Kyverna Therapeutics shares are held by insiders. Comparatively, 5.1% of Xencor shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Xencor has higher revenue and earnings than Kyverna Therapeutics. Xencor is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$2.94	N/A
Xencor	$125.58M	14.45	-$91.92M	-$2.17	N/A

Kyverna Therapeutics has a beta of 1.98, indicating that its share price is 98% more volatile than the broader market. Comparatively, Xencor has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

Summary

Xencor beats Kyverna Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Kyverna Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KYTX vs. The Competition

Export

Metric	Kyverna Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$448.98M	$3.86B	$7.16B	$12.85B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	N/A	8.41	214.39	20.85
Price / Sales	N/A	1,378.88	633.80	90.72
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	1.89	15.12	10.33	6.21
Net Income	-$161.31M	-$22.86M	$3.50B	$358.54M
7 Day Performance	-12.00%	-4.34%	-3.32%	-2.35%
1 Month Performance	-10.15%	0.54%	-0.53%	-3.23%
1 Year Performance	85.20%	40.74%	23.51%	8.79%

Kyverna Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KYTX Kyverna Therapeutics	2.085 of 5 stars	$7.26 -1.2%	$30.00 +313.2%	+85.2%	$448.98M	N/A	N/A	96	Positive News
ZYME Zymeworks	2.9963 of 5 stars	$28.11 -3.7%	$41.00 +45.9%	+66.7%	$1.99B	$37.13M	N/A	460	Positive News
STOK Stoke Therapeutics	3.4571 of 5 stars	$30.05 +0.8%	$44.25 +47.3%	+23.7%	$1.94B	$27.59M	N/A	100	Positive News Analyst Forecast
NBTX Nanobiotix	0.9173 of 5 stars	$38.19 -1.6%	$37.33 -2.2%	+281.5%	$1.93B	$36.87M	N/A	100
VIR Vir Biotechnology	1.861 of 5 stars	$11.18 -1.8%	$21.57 +92.9%	+112.4%	$1.89B	$68.56M	N/A	580	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KYTX) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kyverna Therapeutics (KYTX) Competitors

KYTX vs. ZYME, STOK, NBTX, VIR, and XNCR

How does Kyverna Therapeutics compare to Zymeworks?

Summary

How does Kyverna Therapeutics compare to Stoke Therapeutics?

Summary

How does Kyverna Therapeutics compare to Nanobiotix?

Summary

How does Kyverna Therapeutics compare to Vir Biotechnology?

Summary

How does Kyverna Therapeutics compare to Xencor?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYTX vs. The Competition

Kyverna Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kyverna Therapeutics (KYTX) Competitors

KYTX vs. ZYME, STOK, NBTX, VIR, and XNCR

How does Kyverna Therapeutics compare to Zymeworks?

Do analysts prefer KYTX or ZYME?

Which has higher valuation & earnings, KYTX or ZYME?

Do institutionals & insiders have more ownership in KYTX or ZYME?

Is KYTX or ZYME more profitable?

Which has more risk and volatility, KYTX or ZYME?

Does the media prefer KYTX or ZYME?

Summary

How does Kyverna Therapeutics compare to Stoke Therapeutics?

Which has higher earnings and valuation, STOK or KYTX?

Is STOK or KYTX more profitable?

Do analysts rate STOK or KYTX?

Do institutionals and insiders believe in STOK or KYTX?

Does the media favor STOK or KYTX?

Which has more risk & volatility, STOK or KYTX?

Summary

How does Kyverna Therapeutics compare to Nanobiotix?

Do analysts rate NBTX or KYTX?

Is NBTX or KYTX more profitable?

Which has more volatility & risk, NBTX or KYTX?

Does the media refer more to NBTX or KYTX?

Do insiders and institutionals believe in NBTX or KYTX?

Which has preferable valuation and earnings, NBTX or KYTX?

Summary

How does Kyverna Therapeutics compare to Vir Biotechnology?

Do analysts prefer KYTX or VIR?

Which has more volatility and risk, KYTX or VIR?

Is KYTX or VIR more profitable?

Does the media prefer KYTX or VIR?

Do insiders and institutionals hold more shares of KYTX or VIR?

Which has preferable earnings and valuation, KYTX or VIR?

Summary

How does Kyverna Therapeutics compare to Xencor?

Is KYTX or XNCR more profitable?

Does the media refer more to KYTX or XNCR?

Do analysts prefer KYTX or XNCR?

Do institutionals and insiders hold more shares of KYTX or XNCR?

Which has preferable earnings & valuation, KYTX or XNCR?

Which has more risk and volatility, KYTX or XNCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYTX vs. The Competition

Kyverna Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools